Plexium Unveils Groundbreaking Data on Degrader Programs at AACR 2025 Plexium showcased promising findings from their selective degrader programs targeting SMARCA2, IKZF2, and CDK2 at AACR 2025. The developments illustrate their innovative approach to cancer treatment.

Plexium Unveils Groundbreaking Data on Degrader Programs at AACR 2025 #USA #Chicago #Cancer_Research #Plexium #SMARCA2